-
More than 7,700 hospitals in my country have established an appointment diagnosis and treatment system
Time of Update: 2021-03-26
Medical Network News on March 24, National Health Commission’s Planning Development and Informatization Department Director Mao Qun’an said at a press conference of the National Health Commission on
-
Tide Pharmaceuticals won the title of "Model of Capital Civilized Unit"
Time of Update: 2021-03-26
The picture above shows the list of pacesetters of civilized units in the capital of the Economic Development ZoneThe capital's spiritual civilization creation activity is held every three years and is an important honor in the field of the capital's spiritual civilization construction.
-
Yiling Pharmaceutical Dextromethorphan Hydrobromide Tablets Passed the Consistency Evaluation
Time of Update: 2021-03-26
On March 24, Yiling Pharmaceutical announced that it received the "Drug Supplementary Application Approval Notice" for dextromethorphan hydrobromide tablets approved and issued by the National Medical Products Administration.
At present, only 2 dextromethorphan hydrobromide tablets in China have passed the consistency evaluation (including the products approved by the company this time).
-
Health Commission: 11 new confirmed cases, all imported from abroad
Time of Update: 2021-03-26
As of 24:00 on March 24, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 165 confirmed cases (no severe cases), a total of 85,335 cured and discharged cases, and a total of 4,636 deaths.
-
Xiao Guoliang, independent director of Zhenbaodao Pharmaceutical, resigns
Time of Update: 2021-03-26
Due to personal reasons, Xiao Guoliang applied to resign from the company's fourth independent director and the relevant positions of the special committees under the board of directors.
-
Luye Pharma grants the exclusive rights to the Japanese market of Towa Pharmaceuticals' Mindahi Transdermal Patch
Time of Update: 2021-03-25
In addition, Luye Pharma's tomorrow-day transdermal patch of Liss has been launched in the United States, Europe, China and some Asian countries, and has a good record of product development and sales.
-
Two key Phase 3 clinical trials of Astellas fezolinetant reach the primary endpoint
Time of Update: 2021-03-25
CompilationFan DongdongA few days ago, Japanese pharmaceutical company Astellas Pharma announced that its oral non-hormonal treatment of moderate to severe menopausal vasomotor symptoms (VMS) fezolinetant has achieved positive results in two phase 3 phases.
-
BeiGene introduces exclusive development rights for new TNFR2 antagonists
Time of Update: 2021-03-25
On February 18, BeiGene announced that it had reached a cooperative development agreement with Boston Immune Technologies and Therapeutics (hereinafter referred to as "BITT") on the tumor necrosis factor receptor type 2 (TNFR2) antagonist antibody BITR2101, and obtained BITR2101 in Asia (Japan).
-
In 2020, the global pharmaceutical giant's autoimmune disease business ranked TOP10
Time of Update: 2021-03-25
According to Sanofi’s 2020 financial report, among the products with sales exceeding 1 billion euros, only Dupixent and Aubagio in the self-improvement field have achieved positive growth due to demand growth and price increases.
-
Gan Lai announces that the THR-β agonist ASC41 achieves good results in overweight and obese subjects
Time of Update: 2021-03-25
Preliminary data showed that during the 28-day oral administration treatment, compared with the placebo group, the low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and total cholesterol (TC) indicators of subjects in the ASC41 group were all Shows a sustained, clinically significant and statistically significant decrease.
-
Guidelines for the rectification of defects in drug production supervision and inspection (trial) were issued
Time of Update: 2021-03-25
222 “”，，，，，《》《》《》《》，，《（）》，。 。 2021210 （） 、 、、、，。 、，，。 The holders of drug marketing licenses and drug manufacturers may refer to this guideline for risk reminders or warnings made by the L
-
The Ministry of Industry and Information Technology publicly solicits opinions on the development plan of the medical equipment industry
Time of Update: 2021-03-25
This plan proposes that the product performance and quality of my country's medical equipment will reach international standards by 2025, and it is estimated that 6 to 8 companies will enter the top 50 global medical equipment industry.
-
Two batches of medicines were recalled: some medicines should be sold with balances
Time of Update: 2021-03-25
Is this error serious?We know one thing that can completely delegate the right to buy or not to the patient's own hands, called OTC medication, such as Fengyoujing;Those who leave the right to buy to the doctor are called prescription drugs;The right to use medicines must be left to nurses, most of which are injections.
-
After the Spring Festival, the Central Commission for Discipline Inspection issued a document naming medical and pharmaceutical corruption for the first time
Time of Update: 2021-03-25
Entering February , many key few were investigated According to Cyberlan’s observations, the National Supervision Commission of the Central Commission for Discipline Inspection previously published an article on the official website of “Anti-corruption in the Medical Field: Someone Asks the Pulse with One Hand, and Swallows Gold in His Sleeve”, pointing out that hospital leaders such as the hospital director, as a key minority, are involved in many cases The problem.
-
Hausen introduced first in class oral antifungal drugs
Time of Update: 2021-03-25
Scynexis has submitted to the FDA a marketing application for the Ibrexafungerp oral preparation for the treatment of vulvovaginal candidiasis (vaginal yeast infection), and the scheduled approval period for PDUFA is June 1, 2021.
-
Teyi Pharmaceutical's sulfadiazine tablets passed the consistency evaluation for the first time
Time of Update: 2021-03-25
The company's drug sulfadiazine tablets passed the consistency evaluation for the first time.
5. The second-choice drug to treat cervicitis and urethritis caused by Chlamydia trachomatis.
6. The second choice drug for the treatment of neonatal inclusion body conjunctivitis caused by Chlamydia trachomatis.
-
Development and Reform Commission: A large number of medical institutions are ready to be built (list attached)
Time of Update: 2021-03-25
Shanghai First People's Hospital Ophthalmology Clinic Clinic The Ophthalmology Clinical Diagnosis and Treatment Center of Shanghai First People's Hospital is the backing unit of the National Eye Disease Clinical Medicine Research Center, and it is also the first batch of social and people's livelihood medical and health projects in Shanghai's "13th Five-Year Plan".
-
The Central Commission for Discipline Inspection: 290 pharmaceutical companies whose sales expenses were investigated
Time of Update: 2021-03-25
On January 28, according to the website of the State Supervision Commission of the Central Commission for Discipline Inspection, from 2011 to 2019, Hu Shuangfei used his position as the director of the anesthesiology department to provide assistance in the access, sales, and use of drugs from several pharmaceutical companies.
-
Huaxi Biological Appoints Gao Yi as Deputy General Manager
Time of Update: 2021-03-25
Gao Yi as the company’s deputy general manager for a term of office.
, and Huaxi International Medical Skin Management Technology (Beijing) Co.
-
10 domestic 1 class of new drugs "on the market take off"! It's sunny, Hengrui, Howson is on
Time of Update: 2021-03-25
Its medical insurance effect is fully reflected in 2019, when the terminal sales of Anlotinib in China's public medical institutions exceeded 2 billion yuan, and it became a veritable large variety in the second year of its listing.
